Lesch-Nyhan Syndrome

Etiology

Lesch-Nyhan syndrome is an X-linked recessive disorder resulting from a likely pathogenic or pathogenic variant in the HPRT1 gene, located at Xq26-q27 on the long arm of the X chromosome. Approximately one-third of cases arise de novo.[3] Although only a single gene is associated with this syndrome, over 600 likely pathogenic or pathogenic variants have been identified, each leading to varying levels of clinical severity, making HPRT enzyme deficiency a spectrum rather than a single disease. Boys who inherit the defective X chromosome from carrier mothers manifest the disease. Girls are predominantly asymptomatic carriers but may manifest the disease if skewed X-chromosome inactivation preferentially silences the normal allele, allowing predominant expression of the affected HPRT1 gene.[4]

Epidemiology

Prevalence estimates vary by population: approximately 1 in 380,000 live births in Canada, 1 in 235,000 in Spain, and as low as 1 in 2 million in the United Kingdom.[3][5][6] The discrepancy may reflect differences in ascertainment methods and diagnostic access.

Pathophysiology

HPRT catalyzes the conversion of hypoxanthine and guanine to inosine monophosphate and guanosine monophosphate, respectively, within the purine salvage pathway, using phosphoribosyl pyrophosphate as a cosubstrate. In HPRT deficiency, hypoxanthine and guanine accumulate through 2 principal mechanisms: impaired reutilization for nucleotide synthesis and increased availability of phosphoribosyl pyrophosphate, which drives de novo purine synthesis. Excess inosine monophosphate generated via the de novo pathway is subsequently degraded to hypoxanthine and ultimately oxidized to uric acid. Overproduction of uric acid leads to hyperuricemia and its clinical sequelae, including nephrolithiasis and urate deposition in joints and soft tissues (tophi).

The pathophysiology underlying the neurological manifestations of Lesch–Nyhan syndrome remains incompletely understood. Hyperuricemia alone is unlikely to account for neurological features because patients with milder HPRT deficiency do not exhibit significant neurological involvement. A leading hypothesis implicates disordered dopaminergic neurotransmission.[7] Impaired purine recycling may disrupt dopaminergic neuron development because guanosine triphosphate, a product of the purine salvage pathway, is required for tetrahydrobiopterin synthesis, a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. Additionally, relative depletion of guanosine triphosphate may affect intracellular signaling cascades critical for dopaminergic neuron differentiation and survival. Brain regions with high dopaminergic activity, particularly the basal ganglia, including the caudate nucleus, putamen, and nucleus accumbens, are preferentially affected, correlating with the characteristic movement disorders and behavioral abnormalities. Results from positron emission tomography studies and cerebrospinal fluid analyses demonstrated alterations in dopamine function and its metabolites, supporting this hypothesis.[8] The mechanisms underlying self-injurious behavior remain poorly elucidated and are likely multifactorial, involving complex interactions among neurochemical abnormalities, basal ganglia dysfunction, and behavioral dysregulation.[9] 

History and Physical

Individuals with this disease are asymptomatic at birth, with normal prenatal growth and development. Although hyperuricemia is typically present at birth, the only clinical presentation in the early days of life may be orange-colored crystals in the diapers. Eventually, hyperuricemia leads to crystalluria, urolithiasis, nephrolithiasis, gout, and juvenile arthritis. Because hyperuricemia is present in all variants of HPRT deficiency, regardless of severity, the likelihood of neurodevelopmental abnormalities cannot be predicted without measuring enzyme activity.

Neurological features become noticeable by 4 months of age. Hypotonia and developmental delay are common early signs. Infants may also have nonspecific symptoms, such as recurrent vomiting, dysphagia, or difficulty managing secretions. Extrapyramidal signs begin to appear around 8 to 12 months of age, with dystonia being the most common manifestation. Motor symptoms in Lesch–Nyhan syndrome are hypotonia superimposed on severe action dystonia. In almost all cases, dystonia progresses to a point where individuals cannot attain milestones, such as crawling and walking, and eventually become wheelchair dependent. Involuntary movements, such as choreoathetosis and ballismus, develop within the first few years. Features such as dysarthria, dysphagia, and opisthotonus have also been frequently reported. Pyramidal signs (spasticity and hyperreflexia) can develop in the initial years or may not be apparent until later years. Epilepsy is relatively common, occurring in approximately one-third of patients, and may present with generalized tonic–clonic seizures, status epilepticus, epileptic spasms with hypsarrhythmic electroencephalographic patterns, or subclinical seizures, typically with childhood onset. Apnea has been described in association with subclinical seizures and may contribute to respiratory arrest and sudden death.[7]

Cognitive impairment is common; however, its precise severity is difficult to quantify, because standardized testing is often confounded by significant motor dysfunction and dysarthria. Although verbal performance may be disproportionately affected, nonverbal cognitive abilities are relatively preserved in many patients.[3] Self-injurious behavior is the hallmark feature of Lesch–Nyhan syndrome, occurring in approximately 85% of affected individuals and typically absent in milder HPRT variants. Self-injurious behavior commonly involves biting of the lips, digits, and cheeks, leading to significant tissue damage, infection, bleeding, and scarring. Self-injurious behavior typically emerges between 2 and 4 years of age, often coinciding with tooth eruption, though teething itself does not cause the behavior. Importantly, pain perception and other sensory modalities remain intact;[3] self-injurious behavior is considered a compulsive behavioral phenomenon rather than a consequence of sensory deficit. Additional behaviors, such as head-banging, extremity-banging, eye-poking, and compulsive aggression toward others (eg, pinching, hitting, spitting, or verbal outbursts), have also been described.[9][10] Notably, patients frequently express remorse once the compulsive episode subsides. Megaloblastic anemia is a common hematologic feature of HPRT deficiency, reported in 81% to 92% of individuals with Lesch–Nyhan syndrome. The absence of megaloblastic anemia should prompt evaluation for coexisting conditions, such as iron deficiency, thalassemia, or chronic disease, that may mask the typical hematologic findings.[11]

Evaluation

The relatively late emergence of self-injurious behavior, a distinguishing feature of classic Lesch-Nyhan syndrome, and the lack of newborn screening methodology may contribute to delayed diagnosis (median age of diagnosis is 2 years) if earlier clinical signs are overlooked. The presence of developmental delay in conjunction with hyperuricemia should strongly suggest HPRT deficiency and prompt targeted evaluation. Biochemically, elevated serum uric acid levels (greater than 8 mg/dL in adolescents and adults) and increased urinary uric acid excretion (urinary uric acid to creatinine ratio ≥ 3:1 to 4:1) are suggestive findings; however, these markers lack sensitivity and specificity for definitive diagnosis.

Neuroimaging studies are generally of low diagnostic yield because most patients do not exhibit specific structural abnormalities. Some reports described reduced intracranial volume, particularly in the basal ganglia, frontotemporal and limbic regions, and white matter. In classic Lesch–Nyhan syndrome, decreased volume in the ventral striatum and prefrontal cortex has been observed. These findings support the concept of functional impairment associated with disordered neurotransmitter metabolism, although the precise mechanisms remain poorly defined.

Definitive diagnosis relies on enzymatic or molecular confirmation. Enzymatic testing measures HPRT activity in erythrocyte lysates, lymphocytes, or cultured fibroblasts and remains a reliable diagnostic modality. Molecular genetic testing involves sequencing of the HPRT1 gene to identify pathogenic variants. Duplications, deletions, or exon-level rearrangements can result in varying degrees of enzyme deficiency and corresponding phenotypic severity.

Several metabolic biomarkers have been proposed to support the diagnosis. Abnormal red blood cell metabolite profiles, including elevations in 5-aminoimidazole-4-carboxamide ribonucleotide, 5-aminoimidazole-4-carboxamide ribonucleotide triphosphate, vitamin B3 (niacin or niacinamide), and succinyladenosine monophosphate, or marked depletion of adenosine triphosphate, have been reported to be associated with HPRT deficiency.[12]

Additional investigations may be useful in clinical evaluation, including a complete blood count to assess for megaloblastic anemia and electroencephalography in patients with suspected seizure activity that contributes to inattention or episodic events.[7] Given the X-linked recessive inheritance pattern, genetic counseling is strongly recommended for families with a history of Lesch–Nyhan syndrome. Prenatal diagnosis can be established through chorionic villus sampling or amniocentesis, allowing early identification and informed reproductive decision-making.

Treatment / Management

Management of Lesch–Nyhan syndrome is directed toward 2 principal domains: control of hyperuricemia and treatment of neurological and behavioral manifestations. Reduction of uric acid overproduction is achieved with xanthine oxidase inhibitors. Allopurinol remains the mainstay of therapy and should be initiated early because hyperuricemia is present from birth. By inhibiting conversion of hypoxanthine and xanthine to uric acid, allopurinol effectively prevents gout, nephrolithiasis, and tophaceous deposits. Long-term use is generally safe when dosing is carefully adjusted to avoid xanthine stone formation. Rare but serious adverse effects include hypersensitivity reactions, Stevens–Johnson syndrome, and toxic epidermal necrolysis. Febuxostat may be considered in patients who are intolerant to allopurinol.[2] Notably, urate-lowering therapy does not modify neurological or cognitive outcomes.

Neurological dysfunction, including dystonia and self-injurious behavior, remains challenging to treat because the underlying pathophysiology remains incompletely understood and is thought to involve dopaminergic dysfunction within the basal ganglia. Pharmacologic strategies have yielded variable results. Levodopa-carbidopa has shown inconsistent benefit and may exacerbate dystonia or hyperactivity in some patients. Results from a recent case report suggested that very early initiation of levodopa-carbidopa, before the emergence of self-injurious behavior, may delay or prevent its onset.[13] However, the observation requires further data. Tetrabenazine and intrathecal baclofen have demonstrated improvement in selected cases. S-adenosylmethionine, a methyl donor involved in purine metabolism, has been associated with reduced self-injurious behavior and mood stabilization in case reports, particularly when combined with antipsychotics such as risperidone; however, response may be age-dependent and requires further validation. Gabapentin has been used for motor symptoms, pain control, and behavioral stabilization. Carbamazepine, titrated to therapeutic serum levels, has been reported to reduce self-injurious behavior, with symptom recurrence upon withdrawal. Selective serotonin reuptake inhibitors, sometimes combined with dietary serotonergic strategies, and atypical antipsychotics such as risperidone may help mitigate behavioral disturbances.[14] Bilateral injection of botulinum toxin type A into the masseter muscles inhibits the presynaptic release of acetylcholine, leading to temporary muscle weakness and impaired function. However, repeated injections are needed. Alongside botulinum toxin therapy, various pharmacological agents, including benzodiazepines, neuroleptics, antidepressants, chloral hydrate, and anticonvulsants, have also been used to treat and suppress such compulsive actions.[15][16](A1)

Deep brain stimulation has shown promise in selected cases, with reported improvements in dystonia and reductions or cessation of self-injurious behavior; however, procedural risks, such as infection and hardware complications, necessitate careful patient selection. Preclinical research into gene therapy (including CRISPR-based gene correction) and enzyme replacement is ongoing, but no human clinical trials have been completed to date.[16] Spasticity and pyramidal features may be treated with baclofen or benzodiazepines, alongside comprehensive physical rehabilitation to prevent contractures and deformities. Behavioral management requires an interdisciplinary approach integrating psychiatric, medical, and supportive strategies. Stress reduction is essential because emotional distress often exacerbates self-injurious behavior. Aversive conditioning techniques are discouraged because they may worsen compulsive behaviors. Protective measures, including elbow restraints, dental guards, and lip bumpers, are frequently necessary; some patients voluntarily request restraints during periods of heightened compulsion. In refractory cases where conservative measures fail, dental extraction may be required to prevent severe tissue injury.(A1)

Nonpharmacological strategies for self-injurious behavior should be implemented alongside pharmacotherapy. Physical protective devices, including padded arm splints, wheelchair straps, and gloves, are used by nearly all patients and are typically worn for more than 75% of waking hours. Critically, clinicians should understand these devices as protective rather than restrictive; most patients actively request their application and become visibly distressed when the devices are removed because the devices alleviate the anxiety associated with the compulsive urge to self-injure. The Joint Commission and the Centers for Medicare & Medicaid Services have formally exempted these safeguarding devices from standard restraint protocols specifically for individuals with Lesch–Nyhan syndrome. Environmental modifications are equally important: stress reduction, maintenance of familiar routines, and minimization of environmental changes, including limiting unnecessary hospital admissions, significantly reduce episodes of self-injurious behavior because self-injury in Lesch–Nyhan syndrome is strongly exacerbated by stress rather than driven by operant conditioning. Traditional aversive behavioral modification techniques are generally ineffective and may paradoxically worsen self-injurious behavior in this population. Caregiver education regarding these principles is essential because misunderstanding the compulsive nature of self-injurious behavior can lead to inappropriate withdrawal of protective devices or punitive approaches that increase patient distress.[9][17][18] (B3)

Dental management is a critical component of self-injurious behavior prevention, given that oral self-mutilation, particularly biting of the lips, tongue, and buccal mucosa, is the most common and often earliest form of self-injury. Custom-fabricated intraoral devices, including bite-raising occlusal splints and lip bumpers, can deflect soft tissues away from the occlusal surfaces, promote healing of existing injuries, and permit normal jaw function. When intraoral appliances are insufficient, selective extraction of teeth, particularly the deciduous and permanent canines and incisors, may be necessary to prevent ongoing tissue destruction; approximately 60% of patients ultimately undergo some degree of dental extraction. However, early or extensive extraction in young children carries the risk of alveolar bone resorption and subsequent facial disfigurement. Vital pulpotomy with preservation of alveolar bone has been proposed as an intermediate approach that reduces biting force while maintaining facial growth. The choice among these options should be individualized in consultation with a pediatric dentist experienced in treating patients with neurodevelopmental disabilities, and treatment plans should be reassessed because the patient’s dentition and behavioral patterns evolve.[19][20] Experimental approaches, including selective dopamine receptor antagonists, bone marrow transplant, exchange transfusion, and umbilical cord blood transplant, have not demonstrated consistent neurological benefit. Overall, treatment of Lesch–Nyhan syndrome remains largely supportive and symptomatic, underscoring the need for continued research into targeted therapies.(B3)

Differential Diagnosis

Early features, such as dystonia and developmental delay, often result in an initial misdiagnosis of cerebral palsy. Hyperuricemia, a hallmark biochemical finding, is not specific to Lesch–Nyhan syndrome and may also occur in other metabolic disorders associated with purine overproduction, including phosphoribosyl pyrophosphate synthetase hyperactivity and glucose-6-phosphate dehydrogenase deficiency. Self-injurious behavior, while characteristic of classic Lesch–Nyhan syndrome, is also observed in a range of neurodevelopmental and genetic conditions, including Rett syndrome, autism spectrum disorder, Tourette syndrome, Cornelia de Lange syndrome, hereditary sensory neuropathies, familial dysautonomia, and metabolic disorders, such as glucose-6-phosphate dehydrogenase deficiency and phosphoribosyl pyrophosphate synthetase hyperactivity.

Prognosis

Patients with Lesch–Nyhan syndrome generally have a reduced life expectancy, with most individuals rarely surviving beyond their third decade. Renal failure, once a common cause of mortality due to chronic hyperuricemia, has become uncommon with early diagnosis and timely treatment using allopurinol. Current causes of death are primarily related to respiratory complications, including respiratory failure and infections, such as pneumonia. Additionally, sudden unexpected death has been reported in some patients, underscoring the need for vigilant clinical monitoring.[21]

Complications

Uric acid calculi result from precipitation of excess uric acid. Because these calculi are radiolucent, they are not seen on abdominal radiography, which can delay the diagnosis and lead to renal failure. Treatment with allopurinol decreases uric acid production but increases hypoxanthine and xanthine concentrations. Xanthine, being less soluble, can result in xanthine lithiasis, especially if the patient is dehydrated.

Dental guards and other oral protective devices can hamper proper dental hygiene. Extraction of teeth in early childhood can lead to facial disfigurement as children grow. However, failure to extract the teeth can result in tissue damage with worse cosmetic damage. Vital pulpotomy with preservation of alveolar bone can prevent facial deformity associated with tooth extraction.[22][23]